NO20082077L - Spirosykliske quinazolinderivater som PDE7-inhibitorer - Google Patents

Spirosykliske quinazolinderivater som PDE7-inhibitorer

Info

Publication number
NO20082077L
NO20082077L NO20082077A NO20082077A NO20082077L NO 20082077 L NO20082077 L NO 20082077L NO 20082077 A NO20082077 A NO 20082077A NO 20082077 A NO20082077 A NO 20082077A NO 20082077 L NO20082077 L NO 20082077L
Authority
NO
Norway
Prior art keywords
spirocyclic
quinazoline derivatives
pde7 inhibitors
compounds
pde7
Prior art date
Application number
NO20082077A
Other languages
English (en)
Norwegian (no)
Inventor
David James Rawson
Nigel Alan Swain
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NO20082077L publication Critical patent/NO20082077L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20082077A 2005-12-02 2008-05-02 Spirosykliske quinazolinderivater som PDE7-inhibitorer NO20082077L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74185405P 2005-12-02 2005-12-02
US79118606P 2006-04-10 2006-04-10
PCT/IB2006/003388 WO2007063391A2 (fr) 2005-12-02 2006-11-23 Derives spirocycliques

Publications (1)

Publication Number Publication Date
NO20082077L true NO20082077L (no) 2008-06-04

Family

ID=37882213

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082077A NO20082077L (no) 2005-12-02 2008-05-02 Spirosykliske quinazolinderivater som PDE7-inhibitorer

Country Status (22)

Country Link
US (1) US7507742B2 (fr)
EP (1) EP1957467A2 (fr)
JP (1) JP2009517453A (fr)
KR (1) KR101009554B1 (fr)
AP (1) AP2008004470A0 (fr)
AR (1) AR058266A1 (fr)
AU (1) AU2006321349A1 (fr)
BR (1) BRPI0619126A2 (fr)
CA (1) CA2631535C (fr)
CR (1) CR10039A (fr)
EA (1) EA200801145A1 (fr)
EC (1) ECSP088484A (fr)
GT (1) GT200600494A (fr)
MA (1) MA30014B1 (fr)
ME (1) MEP0408A (fr)
NL (1) NL2000336C2 (fr)
NO (1) NO20082077L (fr)
PE (1) PE20071087A1 (fr)
RS (1) RS20080233A (fr)
TW (1) TW200732307A (fr)
UY (1) UY29979A1 (fr)
WO (1) WO2007063391A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
CN101166524B (zh) * 2005-04-28 2010-12-22 辉瑞有限公司 氨基酸衍生物
US20080260643A1 (en) * 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008142550A2 (fr) * 2007-05-24 2008-11-27 Pfizer Limited Dérivés spirocycliques
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2010135468A1 (fr) * 2009-05-19 2010-11-25 Vivia Biotech S.L. Procédés permettant de fournir des essais de médicaments personnalisés ex vivo pour des tumeurs hématologiques
CA2817071C (fr) 2010-11-08 2018-04-24 Omeros Corporation Traitement d'addiction et de troubles de controle des impulsions au moyen d'inhibiteurs de la pde7
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
CA3069432A1 (fr) * 2017-07-12 2019-01-17 Dart Neuroscience, Llc Composes de benzoxazole et de benzofurane substitues utilises en tant qu'inhibiteurs de pde7
WO2024038089A1 (fr) 2022-08-18 2024-02-22 Mitodicure Gmbh Utilisation d'un agent thérapeutique ayant une activité inhibitrice de phosphodiestérase-7 pour le traitement et la prévention de maladies associées à la fatigue, à l'épuisement et/ou à l'intolérance à l'effort chroniques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083772A1 (fr) 2000-04-28 2001-11-08 Merck Patent Gmbh Variant d'epissage de la phosphodiesterase de type 7 de camp (pde7a3)
WO2002076953A1 (fr) 2001-03-21 2002-10-03 Warner-Lambert Company Llc Nouveaux derives spirotricycliques et utilisation de ces derives en tant qu'inhibiteurs de la phosphodiesterase-7
EP1400244A1 (fr) 2002-09-17 2004-03-24 Warner-Lambert Company LLC Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase
AU2006219643A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of PDE7 inhibitors for the treatment of neuropathic pain
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique

Also Published As

Publication number Publication date
US20070129388A1 (en) 2007-06-07
EP1957467A2 (fr) 2008-08-20
AP2008004470A0 (en) 2008-06-30
TW200732307A (en) 2007-09-01
KR20080059338A (ko) 2008-06-26
ECSP088484A (es) 2008-06-30
RS20080233A (en) 2009-07-15
US7507742B2 (en) 2009-03-24
PE20071087A1 (es) 2007-12-29
WO2007063391A3 (fr) 2007-09-13
NL2000336C2 (nl) 2007-08-07
MEP0408A (xx) 2010-02-10
JP2009517453A (ja) 2009-04-30
CA2631535C (fr) 2010-07-27
AR058266A1 (es) 2008-01-30
GT200600494A (es) 2007-07-06
AU2006321349A1 (en) 2007-06-07
WO2007063391A2 (fr) 2007-06-07
CR10039A (es) 2008-07-10
EA200801145A1 (ru) 2008-10-30
BRPI0619126A2 (pt) 2011-09-13
CA2631535A1 (fr) 2007-06-07
NL2000336A1 (nl) 2007-06-05
UY29979A1 (es) 2007-06-29
MA30014B1 (fr) 2008-12-01
KR101009554B1 (ko) 2011-01-18

Similar Documents

Publication Publication Date Title
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
NO20092033L (no) Nye forbindelser
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20064077L (no) Kemokinreseptorantagonister
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
EA200701504A1 (ru) Индолы, пригодные для лечения воспалений
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
BRPI0411365A (pt) derivados de aminopiridina
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
MY148636A (en) Benzimidazole derivatives
NO20055688L (no) Organiske forbindelser
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20053762L (no) Kondensert furanforbindelse.
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
SE0400284D0 (sv) Novel compounds
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
BRPI0714885B8 (pt) compostos terapêuticos e seu uso

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application